Novartis Stock - Weekly outlook with FDA remibrutinib focus and upcoming Q2 earnings

Novartis heads into a busy stretch with FDA interactions on remibrutinib in multiple sclerosis and its next quarterly results on the horizon. A weekly outlook shows how regulatory milestones and earnings timing shape the narrative around the Swiss pharma stock.

Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 13:39 CET. Details in the imprint.

Novartis (CH0012005267) enters this week with investors still digesting recent U.S. regulatory feedback on its multiple sclerosis candidate remibrutinib and looking ahead to the next quarterly earnings date. According to Reuters and company disclosures, pivotal data discussions with the U.S. Food and Drug Administration have advanced the filing path for the BTK inhibitor.

This week’s key drivers

Regulatory momentum around remibrutinib remains a central talking point for Novartis at the start of the week. Reuters recently highlighted that expert feedback on pivotal trial data was discussed with the U.S. Food and Drug Administration, an important step ahead of a multiple sclerosis filing.

The company has positioned remibrutinib as part of its next neurology and immunology wave, which is intended to complement existing multiple sclerosis therapies and support medium-term growth. Against this backdrop, any further FDA interactions or guidance on timelines would be closely watched by the market.

Weekly outlook and earnings calendar

From an earnings perspective, Novartis has already guided investors to its next major date: the company is scheduled to report results on 07/23/2026, according to recent investor materials and calendar data. That puts this week roughly one month ahead of the upcoming quarterly release.

In the weeks leading into results, investors typically focus on prescription trends for key brands, progress on pipeline assets like remibrutinib, and potential updates on portfolio rationalization. For a diversified large-cap pharmaceutical group, these factors help shape expectations for sales growth and margin development over the next few quarters.

The product behind the stock

Novartis generates most of its revenue from innovative prescription medicines, ranging from oncology to cardiovascular and immunology treatments. The company highlights drugs such as Cosentyx for immunology and Entresto for heart failure as core growth pillars alongside a late-stage pipeline that includes remibrutinib in multiple sclerosis.

Where the stock trades today

Novartis shares (CH0012005267) trade on SIX Swiss Exchange at CHF 94.20 as of 06/21/2026, 17:30 CET.

Key facts on Novartis stock

• Company: Novartis AG
• ISIN: CH0012005267
• WKN: 904278
• Ticker: NOVN
• Venue: SIX Swiss Exchange
• Price (as of 06/21/2026, 17:30 CET): 94.20 CHF
• Market cap: 197,500,000,000 CHF (as of 06/21/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: SMI, Stoxx Europe 50
• Next earnings date: 07/23/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.